Uveitis - Market Insight, Epidemiology and Market Forecast - 2027

  • ID: 4330606
  • Drug Pipelines
  • 132 Pages
  • DelveInsight
1 of 4
Thorough Assessment of Competitors, Market, Current Trends & Treatments Along With Upcoming Treatments
The ‘Uveitis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Uveitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Uveitis - Disease Understanding and Treatment Algorithm


The Uveitis market report gives the thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.

Uveitis Epidemiology


The Uveitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covers the prevalence of both Infectious and Non-Infectious Uveitis (NIU). Prevalence of NIU is further segmented into four types basis of sub-type [Intermediate Uveitis, Pan-Uveitis, Posterior Uveitis, Anterior noninfectious uveitis (aNIU] in 7MM.

According to the report, the prevalent cases of Uveitis was 706,666 in 2016 in 7 MM, of which 643,721 cases were of Non-Infectious Uveitis (NIU). As per estimations prevalent cases of Uveitis is expected to increase during the study period i.e., 2016-2027. United States account for highest prevalent cases of Uveitis with 392,035 prevalent cases in 2016 followed by France.

Uveitis Drug Chapters


This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market of Uveitis is dominated with corticosteroids, immunosuppressants and biologics. Off-label corticosteroids, immunosuppressive and biologics are also being used for Uveitis. Corticosteroids are used as first line of therapy for treatment of Uveitis. Currently four corticosteroids namely Durezol, Retisert, Ozurdex and Triesence are being used. The first approved monoclonal antibody approved for the treatment of Uveitis was Humira (Adalimumab). This report includes detailed chapters of marketed along with the promising upcoming therapies.

Uveitis Market Outlook


The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Uveitis market is expected to grow during the forecasted period of 2018-2027 at a CAGR of XX% owing to the launch of nine drugs (presently in Phase III). Uveitis Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.

Uveitis Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Uveitis Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Uveitis Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Uveitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Uveitis market
  • To understand the future market competition in the Uveitis market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Report Introduction

2. Uveitis Market Overview at a Glance
2.1. Total Market Share Distribution Of Uveitis For 7 MM In 2016
2.2. Total Market Share Distribution Of Uveitis For 7 Mmin 2025

3. Uveitis: Overview
3.1. Classification Of Uveitis
3.2. Pathophysiology
3.3. Symptoms Of Uveitis
3.4. Etiology Of Uveitis
3.5. Diagnosis Of Uveitis
3.6. Treatment Of Uveitis

4. Epidemiology and Patient Population
4.1. Key Points
4.1.1. Population And Forecast Parameters
4.1.2. Prevalent Population of Uveitis in 7MM
4.1.3. Region-Wise Prevalent Population Of Uveitis
4.1.4. Region-Wise Prevalent Population Of Non-Infectious Uveitis (NIU)
4.2. United States
4.2.1. Prevalent Population Of Uveitis
4.2.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU)
4.3. Germany
4.3.1. Prevalent Population Of Uveitis
4.3.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU)
4.4. France
4.4.1. Prevalent Population Of Uveitis
4.4.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU)
4.5. Italy
4.5.1. Prevalent Population Of Uveitis
4.5.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU)
4.6. Spain
4.6.1. Prevalent Population Of Uveitis
4.6.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU)
4.7. United Kingdom
4.7.1. Prevalent Population Of Uveitis
4.7.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU)
4.8. Japan
4.8.1. Prevalent Population Of Uveitis
4.8.2. Sub-Type Specific Prevalent Population Of Non-Infectious Uveitis (NIU)

5. Treatment Algorithm
5.1. First Line Of Therapy: Corticosteroids
5.2. Second Line Of Therapy: Immunosuppressants
5.3. Third Line Of Therapy: Biologics

6. Current Unmet Needs of Uveitis

7. Marketed Drugs
7.1. Durezol
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Safety And Efficacy
7.1.6. Side Effects
7.1.7. SWOT Analysis
7.2. Triesence
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Safety And Efficacy
7.2.6. Side Effects
7.2.7. SWOT Analysis
7.3. Retisert
7.3.1. Product Description
7.3.2. Regulatory Milestones
7.3.3. Advantages & Disadvantages
7.3.4. Product Profile
7.3.5. Safety
7.3.6. Efficacy
7.3.7. Side Effects
7.3.8. SWOT Analysis
7.4. Ozurdex
7.4.1. Product Description
7.4.2. Regulatory Milestones
7.4.3. Advantages & Disadvantages
7.4.4. Product Profile
7.4.5. Efficacy
7.4.6. Safety
7.4.7. Side Effects
7.4.8. SWOT Analysis
7.5. Humira
7.5.1. Product Description
7.5.2. Regulatory Milestones
7.5.3. Advantages & Disadvantages
7.5.4. Product Profile
7.5.5. Safety And Efficay
7.5.6. Side Effects
7.5.7. SWOT Analysis

8. Emerging Drugs Analysis
8.1. Phase III Drugs Analysis- Corticosteroids
8.2. Phase III Drugs Analysis-Immunosuppressants
8.3. Phase II Drugs Analysis-Biologics
8.4. Emerging Drugs: Phase III Therapeutics
8.4.1. ADX-102
8.4.1.1. Product Description
8.4.1.2. Clinical Development
8.4.1.3. Advantages & Disadvantages
8.4.1.4. Product Profile
8.4.1.5. Safety And Efficacy
8.4.1.6. Clinical Pipeline Activity
8.4.1.7. Ongoing Trials Information
8.4.1.8. Clinical Trial By Phase
8.4.1.9. SWOT Analysis
8.4.2. Durasert
8.4.2.1. Product Description
8.4.2.2. Clinical Development
8.4.2.3. Advantages & Disadvantages
8.4.2.4. Product Profile
8.4.2.5. Safety And Efficacy
8.4.2.6. Side Effects
8.4.2.7. Clinical Pipeline Activity
8.4.2.8. Ongoing Trials Information
8.4.2.9. Clinical Trial By Phase
8.4.2.10. SWOT Analysis
8.4.3. Sirolimus
8.4.3.1. Product Description
8.4.3.2. Regulatory Milestones
8.4.3.3. Clinical Development
8.4.3.4. Advantages & Disadvantages
8.4.3.5. Product Profile
8.4.3.6. Safety And Efficacy
8.4.3.7. Clinical Pipeline Activity
8.4.3.8. Ongoing Trials Information
8.4.3.9. Clinical Trial By Phase
8.4.3.10. SWOT Analysis
8.4.4. EGP-437
8.4.4.1. Product Descripion
8.4.4.2. Regulatory Milestones
8.4.4.3. Clinical Development
8.4.4.4. Advantages & Disadvantages
8.4.4.5. Product Profile
8.4.4.6. Safety And Efficacy
8.4.4.7. Side Effects
8.4.4.8. Clinical Pipeline Activity
8.4.4.9. Ongoing Trials Information
8.4.4.10. Clinical Trial By Phase
8.4.4.11. SWOT Analysis
8.5. Emerging Drugs: Phase II Therapeutics
8.5.1. Sarilumab
8.5.1.1. Product Description
8.5.1.2. Product Development Activities
8.5.1.3. Clinical Development
8.5.1.4. Advantages & Disadvantages
8.5.1.5. Product Profile
8.5.1.6. Safety And Efficacy
8.5.1.7. Clinical Pipeline Activity
8.5.1.8. Clinical Trial By Phase

9. Market Size of Uveitis in 7MM
9.1. 7 Major Market Outlook
9.2. Market Size Of Uveitis In 7MM
9.3. Region Wisemarket Size Of Uveitis
9.3.1. United States
9.3.1.1. Market Outlook
9.3.1.2. Market Size
9.3.2. EU5
9.3.2.1. Market Outlook
9.3.2.2. Germany Market Size
9.3.2.3. France Market Size
9.3.2.4. Italy Market Size
9.3.2.5. Spain Market Size
9.3.2.6. United Kingdommarket Size
9.3.3. Japan
9.3.3.1. Market Outlook
9.3.3.2. Market Size

10. Appendix
10.1. Report Methodology

11. Consulting Services

12. Disclaimer

13. About the Publisher

List of Tables:
Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025)
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025)
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025)
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025)
Table 5: Sub-type Specific Prevalent Population ofUveitis in United States (2015-2025)
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025)
Table 7: Sub-type Specific Prevalent Population of Uveitis in Germany (2015-2025)
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025)
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025)
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025)
Table 11: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025)
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain (2015-2025)
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025)
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025)
Table 15: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025)
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025)
Table 17: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025)
Table 18: First Line of Therapy of the treatment of Uveitis, 2016
Table 19: Marketed Drugs for Uveitis
Table 20: Comparison of Phase-III drugs (Corticosteroids)
Table 21: Comparison of Phase-III drugs (Corticosteroids)
Table 22: Phase II Drugs Analysis- Biologics
Table 23:ADX-102, Clinical Trials by Zone, 2017
Table 24:Clinical Trials by Recruitment status, 2017
Table 25: Durasert, Clinical Trials by Zone, 2017
Table 26: Clinical Trials by Recruitment status, 2017
Table 27:Sirolimus, Clinical Trials by Zone, 2017
Table 28:Clinical Trials by Recruitment status, 2016
Table 29:EGP-437, Clinical Trials by Zone, 2017
Table 30 :Clinical Trials by Recruitment status, 2017
Table 31:Sarilumab, Clinical Trials by Zone, 2017
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025)
Table 33: Market size of Uveitis by Region in USD Million (2015-2025)
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025)
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025)
Table 36: Market Size of Uveitis in France, USD Million (2015-2025)
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025)
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025)
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025)
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025)

List of Figures:
Figure 1: Classification of Uveitis
Figure 2: Diagnosis algorithm for Uveitis
Figure 3: Treatment Regimens
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025)
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025)
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025)
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025)
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025)
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025)
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025)
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025)
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025)
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025)
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025)
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain (2015-2025)
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025)
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025)
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025)
Figure 19: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in Japan (2015-2025)
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025)
Figure 21: Treatment Algorithm of Uveitis
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017
Figure 24: Durasert, Clinical Trials by Zone (%), 2017
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025)
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025)
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025)
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025)
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025)
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025)
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025)
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025)
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll